The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder N Ibrahim 1, A Elzagheid 2, H El-Hashmi 1, K Syrjänen 3, S Alhakim 4 1 - Departments of Pathology and Surgery, African Oncology Institute, Sabratha, Libya. 2 - Department of Pathology, Faculty of Medicine, Al-Arab Medical University, Benghazi, Libya. 3 - Department of Oncology and Radiotherapy, Turku University Hospital, Savitehtaankatu 1 PB 52, FIN-20521, Turku, Finland. 4 - Department of Pathology, National Cancer Institute, Cairo, Egypt.
Libyan J Med 2009; 4(4):143-145 ICID: 890282
Article type: Original article
IC™ Value: 3.89
Abstract provided by Publisher
The expression of EGFR and p53 has not been adequately studied as a prognostic tool in urinary bladder tumors. We analyzed 74 bladder cancer samples from Egypt for EGFR and p53 expression using immunohistochemistry. The tumors were of different histological types, grades and clinical stages, and with established lymph node status. Almost 61% of the tumors showed positive membranous EGFR expression and 74.3% had positive nuclear staining of p53. Analysis of correlation of the IHC staining with clinical variables showed a significant correlation only between EGFR expression and histological type (p=0.002, ANOVA), in that the expression was higher in squamous cell carcinomas than in other histological types. There were no significant correlations between p53 or EGFR with the other clinicopathological variables, including age, sex, staging, grading, and lymph node status. Further studies are needed to determine if EGFR and p53 might be used as prognostic tools in bladder cancer.